Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
OMTX705, a Novel FAP-Targeting ADC Demonstrates Activity in Chemotherapy and Pembrolizumab-Resistant Solid Tumor Models.
Fabre M, Ferrer C, Domínguez-Hormaetxe S, Bockorny B, Murias L, Seifert O, Eisler SA, Kontermann RE, Pfizenmaier K, Lee SY, Vivanco MD, López-Casas PP, Perea S, Abbas M, Richter W, Simon L, Hidalgo M. Fabre M, et al. Among authors: pfizenmaier k. Clin Cancer Res. 2020 Jul 1;26(13):3420-3430. doi: 10.1158/1078-0432.CCR-19-2238. Epub 2020 Mar 11. Clin Cancer Res. 2020. PMID: 32161121
Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma.
Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ordóñez JL, Domínguez S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frías MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler K, Seifert O, Kontermann R, Pfizenmaier K, Simón L, Fabre M, Carcaboso ÁM, Ludwig JA, de Álava E. Puerto-Camacho P, et al. Among authors: pfizenmaier k. Clin Cancer Res. 2019 Apr 1;25(7):2228-2240. doi: 10.1158/1078-0432.CCR-18-0936. Epub 2018 Nov 12. Clin Cancer Res. 2019. PMID: 30420447 Free PMC article.
An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.
Siegemund M, Seifert O, Zarani M, Džinić T, De Leo V, Göttsch D, Münkel S, Hutt M, Pfizenmaier K, Kontermann RE. Siegemund M, et al. Among authors: pfizenmaier k. MAbs. 2016 Jul;8(5):879-91. doi: 10.1080/19420862.2016.1172163. Epub 2016 Apr 11. MAbs. 2016. PMID: 27064440 Free PMC article.
Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells.
Hutt M, Fellermeier-Kopf S, Seifert O, Schmitt LC, Pfizenmaier K, Kontermann RE. Hutt M, et al. Among authors: pfizenmaier k. Oncotarget. 2018 Jan 31;9(13):11322-11335. doi: 10.18632/oncotarget.24379. eCollection 2018 Feb 16. Oncotarget. 2018. PMID: 29541416 Free PMC article.
Selective Targeting of TNF Receptors as a Novel Therapeutic Approach.
Fischer R, Kontermann RE, Pfizenmaier K. Fischer R, et al. Among authors: pfizenmaier k. Front Cell Dev Biol. 2020 May 26;8:401. doi: 10.3389/fcell.2020.00401. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32528961 Free PMC article. Review.
Tetravalent antibody-scTRAIL fusion proteins with improved properties.
Seifert O, Plappert A, Fellermeier S, Siegemund M, Pfizenmaier K, Kontermann RE. Seifert O, et al. Among authors: pfizenmaier k. Mol Cancer Ther. 2014 Jan;13(1):101-11. doi: 10.1158/1535-7163.MCT-13-0396. Epub 2013 Oct 3. Mol Cancer Ther. 2014. PMID: 24092811
Superior Properties of Fc-comprising scTRAIL Fusion Proteins.
Hutt M, Marquardt L, Seifert O, Siegemund M, Müller I, Kulms D, Pfizenmaier K, Kontermann RE. Hutt M, et al. Among authors: pfizenmaier k. Mol Cancer Ther. 2017 Dec;16(12):2792-2802. doi: 10.1158/1535-7163.MCT-17-0551. Epub 2017 Sep 13. Mol Cancer Ther. 2017. PMID: 28904131
251 results